Vanguard Capital Management
CELZ icon

Vanguard Capital Management’s Creative Medical Technology CELZ Stock Holding History

Vanguard Capital Management’s Portfolio CELZ Stock Details CELZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.5K Hold
20,350
– – ﹤0.01% 3981
2026
Q1 		$41.9K Buy
+20,350
New +$39.8K ﹤0.01% 3935

Other funds holding CELZ

AFM
Anson Funds Management Dallas, Texas $1.68B AUM 374.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Vanguard Capital Management's CELZ Position: Q2 2026 in Review

Vanguard Capital Management held its Creative Medical Technology (CELZ) position steady in Q2 2026 at 20,350 shares worth $29.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3981.

Vanguard Capital Management first reported a position in CELZ in Q1 2026 and has held it in 2 quarters since. The position peaked at $41.9K in Q1 2026. 14 funds tracked by Wall St. Rank hold CELZ as of Q2 2026.

  • Vanguard Capital Management held 20,350 shares of Creative Medical Technology worth $29.5K as of Q2 2026.
  • Vanguard Capital Management left its Creative Medical Technology share count unchanged in Q2 2026.
  • Creative Medical Technology made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3981 holding.
  • Vanguard Capital Management first reported a position in Creative Medical Technology in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Creative Medical Technology position peaked at $41.9K in Q1 2026.
  • 14 funds tracked by Wall St. Rank held Creative Medical Technology as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.